Asked if the Trump administration had missed a vital likelihood to snap up extra doses for Americans, a spokeswoman for the Department of Health and Human Services mentioned, “We are confident that we will have 100 million doses of Pfizer’s vaccine as agreed to in our contract, and beyond that, we have five other vaccine candidates, including 100 million doses on the way from Moderna.”
The federal contract signed in July known as for Pfizer to ship 100 million doses by March at a price of $19.50 a dose — if its vaccine labored. It gave the federal government the choice to request 100 million to 500 million extra doses. It was one of six contracts that the Trump administration signed with vaccine makers in a method supposed to hedge its bets and maximize the probabilities of success.
Accounts differ over the timing of the discussions between Pfizer and federal officers about locking in additional doses. Several individuals mentioned that in late summer season or early fall, Pfizer officers repeatedly warned the Trump administration that demand might vastly outstrip provide and urged it to pre-order extra doses, however have been turned down.
One senior administration official, who spoke to reporters on Monday on the situation of anonymity, mentioned that any firm providing a whole lot of thousands and thousands of doses earlier than it had proof its vaccine labored “was just not going to get the government’s money.”
Another particular person accustomed to the negotiations mentioned talks about doable extra doses started in early October. Michael Pratt, a spokesman for the Department of Health and Human Services, declined to remark on the discussions, however mentioned that “an important part of any negotiation is having established timelines for delivery and production amounts.”
In an announcement, Pfizer, an American firm with headquarters in New York, mentioned that “any additional doses beyond the 100 million are subject to a separate and mutually acceptable agreement,” and that “the company is not able to comment on any confidential discussions that may be taking place with the U.S. government.”
So far, solely Pfizer has gained emergency approval from a Western authorities. British regulators approved it lower than per week in the past, after late-stage scientific trial outcomes confirmed the vaccine was about 95 p.c efficient. The Food and Drug Administration is predicted to comply with go well with within the United States as early as this weekend.